Chris started his career as a researcher in BBC Television’s documentaries department and then became a financial journalist. He was previously Investment Banking Correspondent and Senior Corporate Reporter at the Financial Times, Financial Editor of The Independent and a companies writer at the Investors Chronicle. Chris has also worked at communications consultancy Financial Dynamics (now FTI), as an Associate Partner.
- Tel: +44 (0)20 7542 2410
- E-mail: email@example.com
A British lawmaker reckons business should stay out of the debate over UK membership of the EU. Staying above politics may usually be the mark of a good board. But it would be negligent to ignore any material impact on owners and workers from a one-issue referendum.
Philip Hampton is to join drug giant GSK in January, but may not succeed Chris Gent as chairman until next September. The long transition reflects the difficulty of replacing Hampton at state-backed RBS in an election year. For GSK, the ambiguity in board leadership is unhelpful.
Richard Broadbent will struggle to restore market confidence in the UK retailer. This week’s accounting scandal compounds existing concerns about his period at the helm. The priority should be an orderly handover to the right successor. But speed matters too.
- Tesco chairman approaches his sell-by date
- Glencore's capital promises are those of a trader
- London-UK house-price divergence is manna for BoE
- BHP cheer shows premium on focus
- Barclays' new chair does not need to be banker
- UK banks have much to fear from latest probe
- Imperial prepares $7 bln gamble